The medication is the easy part. What determines whether it goes well is dose titration, managing side effects, protecting muscle while you lose fat, and having a plan for what happens after.
Tirzepatide is a dual GLP-1 and GIP receptor agonist, FDA-approved as Zepbound for weight management and Mounjaro for type 2 diabetes. It reduces appetite and slows gastric emptying. Programs here include eligibility screening, dose titration, side effect management, and nutritional monitoring — because the prescription is the smallest part of doing this properly.
Tirzepatide acts on two receptor pathways rather than one. It reduces appetite, slows how quickly the stomach empties, and affects how the body regulates blood sugar and satiety.
What that means practically: you eat less because you're less hungry, and you feel full sooner. It doesn't burn fat directly, and it isn't a substitute for dietary change and activity — it makes those changes considerably easier to sustain.
Why tirzepatide rather than semaglutide: two pathways rather than one, and head-to-head trial data has shown greater average weight reduction. Side effect profiles are broadly similar. Which suits a given patient is a clinical decision, not a blanket rule.
Appetite comes back and regain is common. That's documented in the trial literature, not a failure of the individual.
A meaningful proportion of rapid weight loss is lean tissue, and it increases when protein intake is low.
Neither is a reason not to do it. Both change how you plan it — whether the goal is long-term treatment, a transition to maintenance, or a defined period with an exit. That conversation happens before the first prescription rather than at month nine.
These are the two questions least often raised by programmes that exist mainly to write prescriptions.
Tirzepatide carries a boxed warning and genuine contraindications. Eligibility is assessed before anything is prescribed.
Not everyone who asks is a candidate. Being told so is part of what a physician-directed programme is for.
Almost everyone gets some. Most settle.
Most side effect problems are dose-escalation problems. Moving up too quickly produces more nausea than the result justifies. Slowing titration usually resolves it, which is one of the more useful things about being monitored rather than simply supplied.
A meaningful proportion of weight lost rapidly is lean tissue rather than fat, and that proportion rises when protein intake is low. Which it usually is, because appetite suppression makes protein the hardest thing to eat enough of.
Losing muscle alongside fat means a lower metabolic rate, less strength, and a worse position if weight returns later. It's the least discussed and most consequential part of GLP-1 weight loss.
Nothing injectable fixes it. Adequate daily protein and resistance training are what protect muscle, and they need to happen throughout treatment rather than afterward. Any programme that sells vitamin shots while never mentioning protein is treating the smaller problem.
Usually not the scale — the face.
Facial fat compartments deflate along with fat everywhere else, and because the face has proportionally less to lose, the change shows there sooner. The result can look hollow or aged even when the weight loss itself is exactly what was wanted.
Because this practice both prescribes tirzepatide and performs aesthetic treatment, facial change is tracked during the process rather than addressed once it's obvious. Catching it early generally means less intervention — Sculptra and facial balancing are the usual tools.
These medications work, and the market around them has become a prescription mill in a lot of places. The parts that actually determine how it goes — titrating slowly enough, catching the person who shouldn't be on it, protecting muscle, and knowing what happens when they stop — take time and don't scale. That's the whole difference between a programme and a supply arrangement.
What is tirzepatide and how does it work?
Tirzepatide is a dual receptor agonist acting on both GLP-1 and GIP pathways. It reduces appetite, slows gastric emptying, and affects how the body regulates blood sugar and satiety. It is FDA-approved as Zepbound for chronic weight management in adults meeting specified criteria, and as Mounjaro for type 2 diabetes. It is prescribed as part of a plan that includes dietary change and physical activity, not as a substitute for them.
Why tirzepatide rather than semaglutide?
Tirzepatide acts on two receptor pathways rather than one, and head-to-head trial data has shown greater average weight reduction than semaglutide. That is the basis for the choice. Both have similar gastrointestinal side effect profiles, and which suits a particular patient is a clinical decision made individually.
How much weight will I lose?
That varies substantially and cannot be predicted in advance. Published trial results describe averages across large study populations under controlled conditions with structured dietary and activity support. Individual results depend on starting weight, dose reached and tolerated, diet, activity, other medications, and factors that are not fully understood. Realistic expectations are discussed at consultation.
Who is not a candidate for tirzepatide?
Tirzepatide carries a boxed warning regarding thyroid C-cell tumours and is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. It is not used in pregnancy or when pregnancy is planned. Caution or avoidance applies with a history of pancreatitis, gallbladder disease, gastroparesis, or significant kidney impairment, and in patients taking insulin or sulfonylureas due to hypoglycaemia risk. It is not appropriate for everyone who requests it.
What are the side effects?
Gastrointestinal effects are most common — nausea, vomiting, diarrhoea, constipation, and reduced appetite. These are usually most pronounced after a dose increase and often settle over subsequent weeks. Fatigue is also commonly reported. Less common but serious risks include pancreatitis, gallbladder problems, and dehydration leading to kidney injury. Severe or persistent abdominal pain warrants prompt medical assessment.
What happens when I stop taking it?
Appetite typically returns and weight regain is common after discontinuation, which is documented in the trial literature. Obesity is managed as a chronic condition rather than cured by a course of treatment. This is discussed before starting, because whether a patient intends to continue long term, transition to maintenance, or stop entirely changes how the programme is planned.
Will I lose muscle as well as fat?
A proportion of weight lost during rapid weight loss is lean tissue rather than fat, and that proportion increases when protein intake is inadequate — which it commonly is, since appetite suppression makes protein the hardest macronutrient to hit. Adequate protein and resistance training are the only things that meaningfully protect muscle during weight loss. No injection or supplement substitutes for them.
What nutritional monitoring happens during treatment?
Substantially reduced intake lowers micronutrients alongside calories. Protein intake and activity are discussed as part of the programme, and vitamin B12 status is worth monitoring particularly in patients also taking metformin, which independently impairs B12 absorption.
Does GLP-1 weight loss cause facial volume loss?
Frequently. Facial fat compartments deflate along with fat elsewhere, and because the face has proportionally less to lose the change is often more visible there. Because Plump Medical Spa both prescribes tirzepatide and performs aesthetic treatment, facial change can be tracked during weight loss rather than addressed only once it becomes obvious.
How do I start?
With a consultation. Medical history, current medications, and eligibility are reviewed before anything is prescribed. Plump Medical Spa is at 4667 MacArthur Blvd, Suite 310, Newport Beach, open Tuesday through Saturday, 10am to 6pm. Cherry and CareCredit financing are available.
General information, not medical advice. Tirzepatide is a prescription medication with a boxed warning and significant contraindications. Whether it is appropriate depends on individual medical history and is determined at consultation. Individual results vary and cannot be predicted. Published clinical trial results describe averages across study populations under controlled conditions and do not represent expected outcomes for any individual patient. This page does not constitute a recommendation to use any medication.
Eligibility, medical history, and what you actually want out of it — before anything is prescribed.
4667 MacArthur Blvd, Suite 310 — Newport Beach, CA 92660
(949) 568-7544 — info@plumpmedicalspa.com
Tuesday – Saturday, 10am – 6pm — By Appointment Only